This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Ladies and gentlemen, thank you for standing by and welcome to the R1 RCM Q1 2021 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone keypad. If you require further assistance, please press star 0. I would now like to turn the conference over to your speaker today, Mr. Rahim, Head of Investor Relations. Please go ahead, sir.
spk00: Good morning, everyone, and welcome to the call. Certain statements made during this call may be considered forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In particular, any statements about our future growth, plans, and performance, including statements about our strategic and cost-saving initiatives, our liquidity position, our growth opportunities, and our future financial performance are forward-looking statements. These statements are often identified by the use of words such as anticipate, believe, estimate, expect, intend, design, may, plan, project, would, and similar expressions or variations. Investors are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements made on today's call involve risks and uncertainties. While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. Our actual results and outcomes could differ materially from those included in these forward-looking statements as a result of various factors, including but not limited to the potential impacts of the COVID-19 pandemic and the factors discussed under the heading risk factors in our annual report on our latest Form 10-K and our latest report on Form 10-Q. We will also be referencing non-GAAP metrics on this call. For a reconciliation of the non-GAAP amounts mentioned to their equivalent GAAP amounts, please refer to our press release. Now, I'd like to turn the call over to Joe.
spk05: Thanks, Atif. Good morning, everyone, and thank you for joining us. We issued three announcements this morning, which will be the basis for a substantial portion of the agenda on today's call. In addition to Q1 earnings, we announced an agreement to acquire visit pay. a leader in healthcare consumer payment solutions that simplify and modernize the payment experience for patients while driving improved financial outcomes for providers. The transaction provides a tax benefit valued at approximately $40 million, equating to an effective purchase price of approximately $260 million. We also announced the strategic expansion of our agreement with Ascension along three broad categories – deployment of our PX solution architecture across ambulatory and acute settings of care, expansion of services performed out of the global shared service centers, and expansion of automation use cases across key functions. The new agreement also extends our master services agreement to 2031, effectively a 10-year term. Let me start with a brief recap of Q1 earnings. I'm pleased to report that 2021 is off to a strong start. Our team continues to execute exceptionally well And we are seeing this manifest itself in the results we are delivering for our customers. First quarter revenue of $342.6 million and adjusted EBITDA of $80.4 million were both ahead of the expectations we communicated on our last earnings call. The upside was driven by higher incentive fees and lower operating costs. While patient volumes in aggregate remain below pre-COVID levels, we have successfully navigated the environment over the past year and believe we are very well positioned to serve our customers and the broader end market in the post-COVID environment. The tone and quality of discussions with prospective customers in our pipeline is very encouraging and gives us a high degree of confidence in our goal of signing $4 billion in new end-to-end NPR in 2021. Technology is increasingly becoming the differentiating factor in many decision-making processes. Our patient experience or PX platform is gaining prominence as providers are increasingly inclined to make revenue cycle sourcing decisions based on what's best for their patients over and above other criteria. Additionally, automation presents an opportunity to fundamentally transform the nature of our industry and reduce the heavy reliance on labor that exists today. Our operational control across the entire revenue cycle process provides a unique lens and significant competitive advantage to drive this disruption. These two factors are the driving force behind our continued heavy investment in technology and the strategic rationale for the VisitPay acquisition. Before I discuss VisitPay in detail, let me provide some background on our PX platform. When we embarked on our PX journey in 2016, we had two important ideas in mind. ease the burden on patients when they access health care, and two, provide a seamless, intuitive journey across all care settings. At the time, the strategic potential of a solution such as this was clear. Patients are generally highly dissatisfied with their scheduling, billing, and payment experience, and any transformation of the patient experience could potentially be a meaningful competitive differentiator for us as well as for our customers. Fast forward to today. I'm pleased to say we believe we have the most advanced, comprehensive technology solution to transform the patient experience. Our PX platform is integrated across care settings, ranging from primary care to outpatient settings such as imaging, labs, same-day surgery, all the way through to inpatient surgery. With the acquisitions of SCI Solutions and Tonic last year, we significantly enhanced our in-house ability to digitize order intake, scheduling, registration, and the authorization process, thereby delivering a robust, cost-effective digital front door capability to our customers. As we've deployed our PX solution to customers, we've seen several transformative results. More than 60% of patient registration counters are performed on a self-service basis. NPS scores are above 75, and we have cut time spent on administrative tasks in that. We've also seen an improvement in collection rates and a decline in the percentage of patient accounts that progress to late-stage collection activities that are a well-publicized dissatisfier for patients. These results have fueled our conviction to continue to invest heavily in PMS. The next logical capability to bring in in-house is the technology to modernize the consumer payments ecosystem in health care. Visipay is the leading consumer payments platform with a proven track record of driving improved payment experience and improved financial outcomes for providers. Visipay makes the healthcare financial experience simple and efficient for both patients and providers in several ways. Let me provide a few examples. First, patients can digitally view simple, modern, and unified statements at the guarantor or family level across care centers. This is a critically unmet need in the market today. Second, patients receive coordinated, tailored communications throughout their healthcare journey. These communications, which are driven by machine learning and adapted for patient preference, keep the patient informed and in control of the financial experience. Third, deep integrations with both health plans and HSA administrators offer a uniquely clear and aligned 360-degree view for patients. Fourth, patients receive financing options and anticipate their need for payment flexibility. Advanced machine learning creates personalized payment recommendations that work for each patient's unique needs while improving provider revenue. And finally, with 10 years of curated data from 300 million visits, we believe VisitPay has the most AI-ready data set for patient payment behavior. a vital differentiator as we think about our broader investments in digitization. The patient satisfaction, loyalty, and retention driven by Visipate's platform are significant. Two of the most important outcomes are a 40-point improvement in net promoter score and a 35% improvement in patient yield, which is increasingly important given the increase in patient payment mix over the past several years. By combining visit-based capabilities with R1, we expect to have the richest payment-related functionality healthcare providers can offer their patients, from pre-service through final bill resolution. We're excited about these capabilities, which will round out our PX offering to cover all patient access components, including integrated order and referral management and real-time scheduling with booking and appointment, comprehensive pre-registration, preauthorization, and price estimation before patients arrive for the appointment, contactless check-in and digital pre-service forms when they arrive for the appointment, and seamless digitized bill visibility and payment options pre-visit, at the point of care, and post-visit, with visibility across care settings and intuitive payment choices. We expect to formally launch this comprehensive solution mid-year, and we'll showcase it at the HIMSS conference in August, where we will also hold an investor event to highlight this and other technology initiatives underway at R1. In addition to rounding out our PX platform, VisitPay allows us to establish a leading position in the consumer payments area. Healthcare consumer debt is arguably the largest and most inefficiently managed liability in our services economy. As we seek to solve high value problems, create a competitive advantage for providers, we can't think of a better space for disruptive innovation, and we believe we will be rewarded well for our investments in this area. VisitPay will also advance our technology platform with both access to a robust data set to enhance our AI-based automation roadmap and patient contact capabilities, which will enable us to reduce friction in the patient access and denials management domains. R1 will also gain substantial technical engineering talent as part of this acquisition, which accelerates our technology roadmap. In addition to Visipay's impressive standalone growth trajectory, we are also expecting meaningful cost synergies from the acquisition by deploying Visipay's deep functionality across the $40 billion of NPR we have under management. Over time, we also see significant revenue synergies. Of note, our sales team is excited to communicate our enhanced end-to-end value proposition, since much of VisitPay's installed base lies with large health systems similar to our target base of end-to-end customers. In summary, the rationale for bringing together R1 and VisitPay's capabilities was clearly compelling. Further fueling our conviction were the results at some of our common customers, where we've been able to generate value beyond what either company on a standalone basis would have been able to do. We believe these proof points are replicable across our customer base and a broad set of healthcare providers. Next, let me provide a customer update with a focus on the Ascension agreement and ongoing deployment activities at LifePoint. I'm pleased to announce the strategic expansion of our revenue cycle services agreement with Ascension. This expansion can be broadly categorized into the following three areas. One, comprehensive deployment of our PX technology solutions. across the acute and ambulatory environments. Two, expansion of our scheduling scope and certain patient-facing services through our global delivery centers. And third, approval around a broader application of technology and use cases for automating key functions within our operations. As noted in my first point, Ascension will be standardizing its technology footprint for digital engagement and will now utilize R1's complete PX technology solution for both the acute and ambulatory settings of care. Important to note, this technology expansion also includes the full suite of patient payment capabilities. In addition to the strategic expansion, we have extended our master services agreement with Ascension through April of 2031. We expect this extension to be net favorable over the term of the agreement relative to our prior contract. In addition, the weighted average contract life for our end-to-end contracts is now nine years. This gives us a high degree of visibility as we think about making long-term investments to support future growth. Turning now to LifePoint, onboarding continues to progress on schedule. We initiated Phase 1 onboarding in January and commence Phase 2 in April. To date, we have welcomed over 700 employees from LifePoint to R1, and technology integration for Phase 1 hospitals is currently underway. We expect to commence phase three in July with the goal of completing all deployment activities in mid-2022. On a related note, we are pleased to have welcomed David Dill, LightPoint's CEO and President, to R1's board, deepening our strategic partnership. His depth of healthcare expertise and broad vantage point will be invaluable to the company. Next, I'd like to turn to our automation effort. We are highly committed to this effort as it presents an opportunity to fundamentally transform the industry by reducing the latency and inefficiency that exists in the revenue cycle management infrastructure today. The 15 million tasks we automated by early 2020 delivered approximately $20 million in EBITDA benefit last year. We now have 40 million tasks in production, up from 30 million as we exit in 2020. These 10 million incremental tasks cover eight new routines, and demonstrate an accelerated development pace. The modular nature of our development approach allows us to develop new routines at a faster pace by reusing and adding to existing automation code. Additionally, the investments we have made in additional core capabilities beyond just RPA, including optical character recognition, natural language processing, expert rules of machine learning, workflow integration, and analytics have expanded our automation coverage of any given workflow. In closing, we remain very excited about our business prospects going forward. To recap the key messages from today's call, our team continues to perform exceptionally well, and this is translating directly to our financial performance. With our Q1 results, we are off to a strong start for the year, and look forward to continued strong execution going forward. End-market dynamics remain very favorable, and we have a high degree of confidence in adding $4 billion in NPR from new end-to-end deals in 2021. VisitPay rounds out our PX platform via a market-leading consumer payment platform and establishes a leading position in the broader consumer payments ecosystem. Our expansion of the Ascension Agreement is a meaningful validation of our PX technology solution, and the expansion is net favorable to our prior agreement. We continue to invest heavily in automation, and the modular nature of our development approach allows us to develop new routines at a faster pace. Now I'd like to turn the call over to Rachel.
spk03: Thank you, Joe, and good morning, everyone. We're pleased to report strong first quarter results with revenue of $342.6 million, up 6.9% year over year, and adjusted EBITDA of $80.4 million, up 30.5% year-over-year. Adjusted EBITDA margin for the quarter moved 23.5%, up 430 basis points from 19.2% in Q1 2020, driven largely by significant higher incentive fees. Reviewing the first quarter results in more detail, net operating fees of $286.1 million increased 1.9% or $5.2 million year-over-year, primarily driven by revenue from new customers and partially offset by anticipated COVID-related volume pressure. On a sequential quarterly basis, net operating fees increased $14.7 million, driven by continued recovery in patient volume. Incentive fees of $29 million were up $12.2 million over the prior year and $1.6 million sequentially, driven by strong operational execution. Other revenue, $27.5 million, increased 20.6% or $4.7 million year-over-year, driven by contribution from SEI, which was somewhat offset by lower revenue from physician advisory services due to COVID-related volume decline. The non-GAAP cost of services in Q1 was $242.8 million, compared to $237.6 million last year, driven by costs associated with serving new customers and onboarding life points. Importantly, our automation digitization efforts continue to drive efficiencies, which help keep cost of services flat sequentially and down 330 basis points year over year. Non-GAAP SDNA expenses of $19.4 million were down almost 9% year over year, primarily due to lower travel and marketing costs, as well as corporate cost control actions. On a sequential basis, SDNA costs decreased 3.4 million, as Q4 results included 1.6 million in payroll taxes related to the besting of employee stock awards. Adjusted EBITDA for the quarter was 80.4 million, up 18.8 million, or 30.5% year-over-year. This increase was largely due to higher incentive fees further magnified by our automation and digitization efforts, helping lower costs. Lastly, we incurred 13 million in other costs in Q1, related to the rationalization of our real estate footprint, ongoing COVID related expenses, and costs associated with strategic initiatives, including the visit pay acquisition and the capital structure simplification transaction, which we completed in January. Turning to the balance sheet, cash and cash equivalents at the end of March were $103.5 million compared to $173.8 million at the end of December. Use of cash in the quarter was largely due to the $105 million payment for the conversion of preferred shares to common, as well as capex of $9.6 million. We generated $46 million in cash from operations in Q1, driven by adjusted EBITDA growth in the quarter. We remain focused on generating strong cash flow from operations, and one of our focus areas this year is to carefully manage our AR days, which increased last year primarily due to AR associated with the Redworks and NCI acquisitions. We also expect our other expense lines to moderate, excluding expenses related to M&A activity. Net debt at the end of March, inclusive of restricted cash, was $444.1 million, compared to $379.8 million at the end of December. The increase was driven by use of cash for the capital structure transaction. Available liquidity at the end of Q1 was in excess of $130 million, consistent with commentary on the Q4 earnings call. We believe our liquidity is sufficient to invest in and grow the business while navigating the current environment. In order to provide additional flexibility and to fund the business pay acquisition, we intend to refinance our current credit facilities concurrent with the completion of the acquisition and expect improved liquidity and pricing as a result of the refinancing. Turning to our financial outlook, we continue to expect revenue of $1.41 to $1.46 billion. and adjusted EBITDA of $315 to $330 million for 2021. We continue to assume the patient volumes will remain at 90% to 95% of pre-COVID levels in line with our experience year-to-date across our customer base. We expect to update our guidance after completion of the visit pay acquisition. R1 will acquire the business for approximately $300 million in cash in a transaction that provides a tax benefit valued at approximately $40 million equating to an effective purchase price of approximately $260 million. To give you a sense of VisitPay's financial profile, the growth is strong with greater than 70% compounded annual revenue growth over the 2019 to 2021 period and comes with a very compelling gross margin profile. Beyond 2021, we expect VisitPay to be accretive to growth and margin. Consistent with my comments on our last call, we expect Q2 revenue in the range of $335 to $345 million and adjusted EBITDA of $65 to $75 million. As previously noted, the anticipated sequential decline in adjusted EBITDA is largely a function of upfront costs associated with onboarding the Litecoin contract. Before I conclude, I want to briefly touch on our ESG initiative. We published our inaugural ESG report in March, and we are pleased to have received a lot of positive support and feedback. We seek to enhance the interests of all of our stakeholders through our ESG commitments that are centered on innovation, integrity, and inclusion. Our report can be viewed at r1rcm.com slash ESG, and as always, we welcome your perspectives. In closing, I'm pleased with our continued execution that delivered Q1 results ahead of our expectations. fundamentals of our business remain strong, and we look forward to maintaining the momentum demonstrated in Q1 as the year progresses. Now I'll turn the call over to the operator for Q&A. Operator?
spk01: If you would like to ask an audio question, please press star 1 on your telephone keypad. Again, that's star 1 to ask an audio question. Your first question comes from the line of Sean Dodge with RBC Capital Markets.
spk06: Thanks. Good morning and congratulations on the quarter. On the revenue outlook, Joe, you mentioned a high degree of confidence in your NPR target. Maybe digging into that a little bit more, you've said before you've been very active on the RFP front, including a handful of several large ones. Can you give us a sense of how those are progressing? Are all of them still active? Have some been decided now? And then maybe anything else you can kind of share about sales pipeline, sales outlook, and how we should think about you hitting that $4 billion over the coming quarters?
spk05: Yeah, thanks, Sean. Just a couple of comments to provide additional color on progression of pipeline. The first thing is, I would say, linking to your question, I would say, yes, the RFP activity is active, and we are progressing that nicely through the different phases of the pursuit process, commercial pursuit process. The second thing I would say is our in total active end-to-end pipeline is up 175% since the start of the year. So we're also seeing active opportunities progress to later stages. which underpins some of our view on the year. And then in totality on an end-to-end basis, we're seeing the total pipeline and aggregate grow nicely. So we continue to feel really good about the end-to-end offering and market receptivity, and we're seeing that across the board in that overall commercial pipeline dimensioning. In addition to that, and I think another indicator of the flexibility we have in our offerings, we booked 24 new modular agreements with new customers in Q1. And the overall revenue bookings was 74% ahead of our internal target. So we continue to see just broad-based positive activity in the end market. And, you know, that's some of the dimension that I'd share with you, Sean.
spk06: Okay, great. And then maybe along the lines of what you just announced here with Ascension and the complete adoption there now of your PX solution, If we think about the cross-selling opportunity across the other parts of your current base, can you give us an idea of what proportion is currently using all the components of your PX platform? Maybe just kind of how we should be thinking about the size, the potential around cross-selling into the other parts of the kind of the non-ascension space.
spk05: Right. Yeah, the way I would describe that is with our two probably most mature deployments, that being Ascension and Intermountain. And Ascension and Intermountain have a little bit different strategies as it relates to their digital intake, but But we're pretty penetrated with this announcement on Ascension across those two customer bases. There's some opportunities on the edge. But what I would really point to is the book of business outside of those two anchor customers. Obviously, LifePoint, Quorum, Amita, Rush, Penn State, et cetera. And there, there's significant white space for us to expand into. As I said, increasingly, our goal is seamless integration across care settings, so that's ambulatory, acute, and increasingly based on our development roadmaps, post-acute setting. And then, as well, seamless integration across the workflow. And what I mean by it in terms of workflow, that's the order intake, the referral process, scheduling signals, Financial clearance, i.e., the registration, off, create, et cetera, that process. And then finally, the payment process. So that overall value prop is resonating, and we see strong receptivity to that in our captive end-to-end customers.
spk06: Okay. That's very helpful. Thanks again. Great. Thanks, Sean.
spk01: Your next question comes from the line of Donald Hooker with KeyBank.
spk07: Great. Good morning. I understand the acquisition of VisitPay, but I was curious if you all could provide any detail on VisitPay's financials itself. Like what exactly are you acquiring financially? Is this a company with a little, you know, kind of what kind of revenue should we start building in? And are there large EBITDA losses? Can you elaborate on some of the financials of the company you're acquiring from?
spk05: Yeah, what I would say, Don, is I'll just use a full year kind of basis. So if we look to 2022, we would expect this business to do about $41 million, $42 million in revenue. And we would expect it to contribute conservatively $7 million to $8 million in EBITDA. As Rachel mentioned in her commentary, this business has been growing rapidly. at 70% compounded over the trailing three years. So it's got a very high growth profile and it's got a very compelling gross margin rate that comes with that growth. But maybe equally important, there are significant what I'll call captive operational synergies. And what I mean by that is that's where we're not dependent on the external markets for growth We're, to a large degree, in control of fully deploying the visit pay platform across our contract and book of business. And those synergies come in the form of digitizing interface with the patients around the payment process, which allows us to lower our cost structure. The second thing is improving the yield. which contributes to our KPIs. And the third thing is we think over time we will be able to materially shift onto the VisitPay platform digitized statements or online bill presentation. And today we have a significant amount of cost that still exists in print statement operations. Somewhat tactical, but But it's, without a doubt, from our standpoint, a synergy that we have a high degree of confidence in. The collective bulk of that is probably at maturity more than twice visit page 2022 contributed EBITDA. So when we roll all that in, not even counting for net new growth we think we can go get, we think on a synergized basis with only assuming our operating control synergies, this is a very accretive transaction for us.
spk07: Gotcha.
spk05: And we're getting a very strategic technology capability in the ICBM market.
spk07: Gotcha. I mean, just to be clear, so there's the synergies, which make a ton of sense, that'll probably phase into your P&L over the next few years. And then, you know, just on a standalone basis, you're saying, you know, $41, $42 million is a revenue next year, obviously high growth. Let me just be clear.
spk05: Yeah, growing at 70%, trailing. That growth will come in as the business grows. But it's still, in any scenario, going to be, from our standpoint, looking out past 2022 off of that basis, a very high growth business and a very high margin business.
spk07: Sure. And then maybe just as a follow-up, also would love to hear, and InvisiPay has been around for a while. I think I'm just looking at their – I'm not familiar with them, obviously – um but it looks like they have some nice logos on their website of different health systems they work with some of which are rcm's clients and some which are not um can you just talk about you know kind of any any maybe client introductions or kind of overlap or what their client base looks like yeah no one of the things that um as we looked at the difference um the different uh targets in the patient payment ecosystem
spk05: One of the things we really liked about VisitPay's platform is they've actually served some of the most sophisticated health systems. And you can see that in their logos, as you referenced on. And from our vantage point, that's a really important demonstrated capability that we liked about their profile. We know how hard it is to serve some of the leading health systems. And those are health systems that are run very, very well. So when you see a technology that's driving incremental improvement, whether that be in the patient experience or in the financial outcomes, that is a true proof point from our standpoint to the leading position that VisitPay has. That's the first point. The second point is right after this call, we've got... probably 20 calls with prospects, meaning not current customers, where we're really excited to introduce this acquisition, talk with those potential net new customers about the enhanced value prop we're bringing to the market. And that's an indication, Don, of of some of the growth synergies that in my prior comments I didn't even include. But we do think there's potential over time for those to be significant and potentially outweigh the captive operational synergies that we used in our underwriting case.
spk07: Great. That sounds interesting. Good luck, and thanks for taking my question. Thanks, John.
spk01: Your next question comes from the line of Stephanie Davis with SEB LeRinc.
spk02: Hey, guys. I echo my congrats on a very busy quarter. Thanks, Stephanie. Kind of following on the last question, I was hoping to hear about how you chose Visipay among the many payment providers in the health tech universe. And just given some of your prior investments on the patient experience platform, what nudged you closer to buy over build?
spk05: Yeah. One of the things, as I mentioned, one of the factors for us choosing Visipay was their demonstrated value prop into our target customers. So again, that was without a doubt a factor in terms of our calculus The second thing is we have had an opportunity over the past couple of years to have a BICEL partnership with Visite Bay. Now, what I'll say is we have not taken full advantage of that, you know, just because of all the priorities that we've had ongoing around deployment and growth and absorbing those things. But we know via that partnership and we saw firsthand, you know, the results that we could generate. The third thing is, as we got into deeper discussions with VisitBay, we were really, really impressed with the human capital or the talent they have in the company. And I would particularly emphasize along the following three lines, their growth, their sales team and their channel for growth. The second thing is their marketing and some of the commercialization and productization skills that they have. And then finally, and most importantly, was the technology development profile. And so talent was a big factor for us. And then the third or final thing is really just the advanced analytics and algorithms they have around serving the patient with very tailored financing options. And we think that's a key differentiator above and beyond just a bill presentation platform, which obviously is very, very important. But at the end of the day, those deep insights and the analytics that they've built over the past 10 years, we think are compelling and differentiated to their peers.
spk02: Understood. So kind of adds to your PX development capabilities going forward as well.
spk05: Yeah, I think we're in really good shape from depth of capability in every one of the workflow steps. Where our organic investments have been and are going to continue to be are around the deep integration across the process flows, so across that workflow continuum, and deep development work to ensure we seamlessly integrate across care settings. So I mentioned ambulatory and acute. That was a big strategic driver in our discussions with Ascension. And then I would say, looking forward, we anticipate making significant investments organically via our technology teams around extending that workflow continuum into the post-acute setting of care, which we think there's a significant opportunity. And then the final thing is, From our standpoint, off of the PX platform, we think there's a very logical extension of some of these services to better serve the clinician or the provider. So those are some areas on our internal development roadmap looking forward that we're very focused on.
spk02: Just one last follow-up from me. Just given this acquisition and the extended extension contract, how does it change your relationship with Frisia, if at all? And do you know if extension is still interested in expanding the hardware component given kind of the changing views on that with COVID?
spk05: Yeah. I really don't want to get into – it wouldn't be within my perspective to get into extension strategies from an IT standpoint on hardware. But what I would say is – we're very focused on solving a very complicated problem, which is, and I'll keep referencing this, the integration, the seamless integration in the eyes of the patient across care settings and across workflow. And for us to solve that problem, we have to go very deep on the integration of technology, and that underpins kind of all of our bias and our actions. Now, there will be different personas of customers and there will be customers that don't necessarily want to embark or they're not prepared at this point in time to embark on that journey and they just need a very compartmentalized solution set. And so I think our focus and what I would draw your attention to is our focus is along those lines And we feel and we're hearing from our current customers as well as target customers who by our own admission are the larger kind of integrated health systems that they really would like us to bring that value prop to the market. And so that's where our internal efforts lie, which is maybe not the same end market as some of the intake companies.
spk02: That is a super helpful clarification. Thank you and congrats again.
spk05: Thanks, Stephanie.
spk01: There are no further questions at this time. I would now like to turn the conference back to Joe Flanagan. We do have a question. I'm sorry.
spk05: Go ahead, Gene.
spk04: Thanks, Joe. Good morning, everybody. And congrats on this quarter. Did you talk about the client overlap with Visit Pay, in particular maybe quantifying the market opportunity of the cross-selling into your base and vice versa, excuse me, maybe RCM into their base? And up to this point, do you have any of your own patients' functionality that maybe is going to be replaced or either self-developed with your script library, or are your customers generally using third-party applications for this function now? Thank you.
spk05: Yeah, so let me first cover, just give a little bit more color on client overlap. VisitPay serves Intermountain, so we work with them in that setting. And as I mentioned before, they're partially deployed at Ascension, we will fully deploy the platform at Ascension. And then in our captive book of business, outside of those two anchor clients, there's significant white space for us to deploy. Now, as part of that deployment, we will be displacing third-party patient payment platforms that exist in that third-party span that with our contractual frameworks will transition to our control. And that's very much in line with with comments that I've had in the past where we have an internal technology platform, and we have very broad coverage of the process with our captive technology. We displace and in-source, integrate and simplify for our customers their technology ecosystem, and that will occur with Visipay. If you look at Visipay's outside of primarily Intermountain, And you can see some of their logos on their website, whether that be Inova, Carilion Clinic, Geisinger, Henry Ford. You start to get a sense that, from our standpoint, they've done the hard work of trying to penetrate the leading integrated delivery systems. And that's squarely in our strategic focus from a growth standpoint. It's early innings, we're just starting the process, but I'm generally optimistic that those discussions will receive well and we'll have a lot of focus from our commercial teams to curate those relationships and look to convey the value on a broader basis that we can deliver via partnership. So that's how I would characterize Gene, kind of the spectrum of call it installed base and client potential synergy. very helpful thank you thanks gene um edgy if we if we don't have any more questions uh just uh thank you for your help today moderating the call and thanks everybody for joining us today uh we are very excited about the developments uh that we're announcing and i look forward to updating you on progress on an ongoing basis in future calls thanks again for all your participation thank you for participating in today's conference call you may now disconnect your line at this time
Disclaimer